Latest Intellectual Property News

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

BPH Global has completed its acquisition of Indonesian seaweed assets, establishing a wholly owned subsidiary and launching joint operations aimed at expanding seaweed cultivation and bio-stimulant product development across Asia.

Icetana Limited has announced a fully underwritten renounceable entitlement offer to raise approximately $2.65 million, aiming to bolster sales, marketing, and product development efforts. The offer, priced at $0.02 per new share, opens on February 3 and closes on February 14, 2025.

BPH Energy Limited's December 2024 quarterly report reveals strategic capital placements and investments in hydrogen and medical technology, alongside ongoing regulatory challenges with the PEP-11 permit.

Archer Materials has been granted a pivotal US patent for its Biochip technology, safeguarding its intellectual property and positioning the company for strategic entry into the lucrative US medical diagnostics market.

Wellnex Life has negotiated a delayed and reduced-cost payment arrangement for its Pain Away acquisition, aligning with its upcoming London Stock Exchange dual listing plans. The move supports the company’s growth momentum following record revenues from Pain Away.

Hazer Group has successfully completed its Commercial Demonstration Plant program ahead of schedule, validating its methane pyrolysis technology and securing significant funding to accelerate commercialisation in 2025.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.